<DOC>
	<DOCNO>NCT02669810</DOCNO>
	<brief_summary>The main purpose phase I/IIB evaluate safety , tolerance first efficacy trend intracardiac injection ProtheraCytes ( autologous PB-CD34+ Stem Cells automate ex-vivo expansion StemXpand machine ) patient De Novo acute myocardial infarction decrease ejection fraction . ProtheraCytes reinjected use dedicate catheter push femoral artery leave ventricle , thus avoid open chest surgery .</brief_summary>
	<brief_title>EXpanded CELL ENdocardiac Transplantation ( EXCELLENT )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>De Novo Anterior wall AMI without ST segment elevation detection rise and/or fall cardiac biomarker value ( troponin ) least one value 99th percentile upper reference limit . LVEF ≤ 45 % stent ( ) implantation : Combination LVEF ≤ 45 % anterior akinetic segment ( ) echography Day 2 stent ( ) mplantations Age must ≥ 18 ≤ 75 year Men Nonpregnant nonlactating woman take efficacious contraceptive measure oral contraceptive medication efficacious permanent intrauterine device ( drug elute ) ( IUD ) subcutaneous permanent contraceptive implant menopaused woman ( least 2 year confirm menopause ) surgically sterilize woman . Having previously sign write informed consent prior study specific procedure . LVEF remain ≤ 45 % assessed cMRI Day 7 +/ 2 day stent ( ) implantation . Identification anterior akinetic segment ( ) interest assess cMRI Day 7 +/ 2 day stent ( ) implantation . Identification nonviability anterior segment ( ) interest assess perfusion 99mTc SPECT uptake day Day 7 +/ 2 day Day 10 +/ 2 day stent ( ) implantation . Absence stent ( ) implantation Previous know symptomatic CHF , class II IV ( include ) History CABG surgery History former significant mitral valve replacement surgery heart transplantation . Severe valve disease : mitral , aortic stenosis / insufficiency . Diagnosis nonischemic dilate cardiomyopathy due valvular dysfunction , mitral regurgitation , tachycardia , myocarditis Aortic stenosis determine valve area le 1 cm2 prohibits.catheter access LV Presence prosthetic / mechanical aortic mitral valve heart constrictive device . Documented presence know LV thrombus Sepsis Endocarditis Infectious pericarditis Pericardial tamponade Left ventricular aneurysm , collagen tissue disease Severe peripheral vascular disease preclude femoral artery access determine time original catheterization . Pacemaker , implantable cardiac defibrillator , intracerebral aneurysm clip . History metallic foreign body eye Severe claustrophobia Former current aortic dissection Inadequate bone marrow function : Haemoglobin &lt; 10 g/dL Platelet count &lt; 100 x 109 / L Previous GCSF Hematopoietic Growth Factor administration . Blood transfusion ( ) within previous 4 week ( exclude potential nonautologous ACPs ( Angiogenic Cells Precursors ) harvest blood ) . Hepatic failure history liver cirrhosis hepatic severe impairment . Constitutional acquire coagulopathy Treated chronic renal failure , haemodialysis renal severe impairment ( creatinine clearance &lt; 30ml/min ) . Prior concomitant malignancy except nonmelanoma skin cancer adequately treat situ cervical cancer previous cancer complete response without treatment last 5 year . History prior mediastinal radiation exposure Serious underlie medical condition investigator 's discretion , could impair ability patient participate trial ( e.g . ongoing infection , active autoimmune disease , Amyotrophic Lateral Sclerosis , Systemic Lupus , Multiple Sclerosis ) . Chronic immunomudulatory cytotoxic drug treatment intake . Active bleeding major surgery within 1 month . Human immunodeficiency HIV12 , HTLV1 , HTLV2 ( accord 2006/17/EC ) Hepatitis B ( without prior vaccination ) C ( accord 2006/17/EC ) Syphilis ( accord 2006/17/EC ) Chronic Obstructive Pulmonary Disease . Active participation clinical trial Current recent treatment ( within 60 day period PTCA stent ( ) implantation ) another investigational drug procedure ) . Any coexist medical psychological condition preclude participation study compromise ability give inform consent . Requirement i.v . catecholamine mechanical hemodynamic support ( aortic balloon pump ) Day 7 +/ 2 day Day 10 +/ 2 day stent ( ) implantation . Splenomegaly Phenylacetonuria History ironDextran allergy History murin protein allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>